PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING PEDIATRIC HEREDITARY ANGIOEDEMA ATTACK

摘要

Provided herein are methods of treating and preventing hereditary angioedema attack in pediatric subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 150 mg every two weeks or at about 150 mg every four weeks.